C.R. Bard Agrees to Merge With Becton Dickinson
C.R. Bard (BCR) has agreed to merge with Becton Dickinson (BDX) for $317 per share, creating a stalwart in the medical supplies field.
C.R. Bard (BCR) has agreed to merge with Becton Dickinson (BDX) for $317 per share, creating a stalwart in the medical supplies field.
C.R. Bard (BCR) is a valuable asset to have right now as its a conservative stock that’s has been and is expected to continue to grow profits 13%.
C.R. Bard (BCR) has been making medical products for more than a century, but this conservative stock is still pumping out double-digit profit growth.
Although C.R. Bard (BCR) has been making medical devices for more than 100 years, it’s still delivering double-digit profit growth.
Conservative growth stock C.R. Bard (BCR) reported solid double-digit profit growth and investors took notice, sending shares higher on the news.
Medical device manufacturer C.R. Bard (BCR) is a conservative stock that’s expected to have double-digit profit growth in both 2016 and 2017.
C.R. Bard (BCR) is advancing catheters and stents, and is a good stock for conservative investors when it dips in price.
Medical device maker C.R. Bard (BCR) broke out to new highs after it beat the street, amazing that it could do so with the strong dollar. But at 22x earnings this 11% grower is fairly valued right now.